

Ceftizoxime Sodium Cas No. : 68401-82-1

ceftizoxime, an antibiotic, to help treat your infection. The drug will be either injected into a large muscle (such as your buttock or hip) or added to an intravenous fluid that will drip through a needle or catheter placed in your vein for 30 minutes, two or three times a day.

Active Pharmaceuticals Ingredients Manufacturers




Taj Pharma PDF

Taj Pharmaceuticals Ltd.**Ceftizoxime Sodium****CAS No. : 68401-82-1****Systematic (IUPAC) name**

(6R,7R)-7-[[[(2Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt

Molecular Structure Ceftizoxime sodium, (6R,7R)-7-[[[(2Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt, CAS #: 68401-82-1
Molecular Formula C₁₃H₁₂N₅NaO₅S₂
Molecular Weight 405.38
CAS Registry Number 68401-82-1



ceftizoxime, an antibiotic, to help treat your infection. The drug will be either injected into a large muscle (such as your buttock or hip) or added to an intravenous fluid that will drip through a needle or catheter placed in your vein for 30 minutes, two or three times a day.

Ceftizoxime eliminates bacteria that cause many kinds of infections, including lung, skin, bone, joint, stomach, blood, and urinary tract infections. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

a third-generation cephalosporin antibiotic.

indications It is prescribed in the treatment of infections caused by susceptible bacterial strains (does not include *Pseudomonas aeruginosa*), primarily in the respiratory system, genitourinary system, bone, joints, and skin.

contraindications Known sensitivity to this drug prohibits its use. It is used with caution in patients who are allergic to penicillin.

Side effects Return to top

Ceftizoxime may cause side effects. If you are administering ceftizoxime into a muscle, it may be mixed with lidocaine (Xylocaine) to reduce pain at the injection site. Tell your health care provider if any of these symptoms are severe or do not go away:

- * diarrhea
- * stomach pain
- * upset stomach
- * vomiting

If you experience any of the following symptoms, call your health care provider immediately:

- * unusual bleeding or bruising
- * difficulty breathing
- * itching



Taj Pharmaceuticals Ltd.
Ceftizoxime Sodium

CAS No. 68401-82-1

- * rash
- * hives
- * sore mouth or throat

Dosage and Administration
Adults

IV/IM 1 to 2 g every 8 to 12 h (life-threatening infections:
IV up to 2 g every 4 h or 3 to 4 g every 8 h).
Children older than 6 mo of age

IV/IM 50 mg/kg every 6 to 8 h up to 200 mg/kg/day (max,
12 g/day).



Note /Government Notification: These chemicals are designated as those that are used in the manufacture of the controlled substances and are important to the manufacture of the substances. For any (Control Substance) products Import and Export *** subjected to your country government laws /control substance ACT.

Information: The information on this web page is provided to help you to work safely, but it is intended to be an overview of hazards, not a replacement for a full Material Safety Data Sheet (MSDS). MSDS forms can be downloaded from the web sites of many chemical suppliers. Also that the information on the PTCL Safety web site, where this page was hosted, has been copied onto many other sites, often without permission. If you have any doubts about the veracity of the information that you are viewing, or have any queries, please check the URL that your web browser displays for this page. If the URL begins "www.tajapi.com/www/Denatonium Benzoate.htm/" the page is maintained by the Safety Officer in Physical Chemistry at Oxford University. If not, this page is a copy made by some other person and we have no responsibility for it.

The Controlled Substances Act (CSA) was enacted into law by the Congress of the United States as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970.[1] The CSA is the federal U.S. drug policy under which the manufacture, importation, possession, use and distribution of certain substances is regulated. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs

This document plus the full buyer/ prescribing information, prepared for health professionals can be found at:

<http://www.tajapi.com>

or by contacting the sponsor, Taj Pharmaceuticals Limited., at:

91 022 30601000.

This leaflet was prepared by
Taj Pharmaceuticals Limited,
Mumbai (India).

MPSTJ278

Last revised: 29 August 2009